An Update From the Phase 3 CARES10 Study
January 4, 2021 • Allergy / Immunology, Infectious Diseases, Internal Medicine, Primary Care, Primary Immunodeficiency Content Hub
The phase 3 Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig (CARES10) study was designed to evaluate the safety, efficacy, and pharmacokinetics of a 10% intravenous immunoglobulin in 47 patients with primary immunodeficiency. The primary efficacy end point was to investigate the incidence rate of acute serious bacterial infections per patient-year. Secondary end points included laboratory, clinical, and health-related quality of life measures.
Learn more by clicking here.
